AKR1B10 is no longer only a marker.
It can be touched.
A recent study by Yang et al., published in the Journal of Ethnopharmacology, identifies AKR1B10 as a direct berberine-binding target in experimental NAFLD models.
The important point is not berberine as a supplement.
The important point is AKR1B10.
In this study, AKR1B10 is chemically engaged, enzymatically inhibited, genetically perturbed and functionally connected to lipid and glucose metabolic outputs.
That changes the weight of the argument.
From marker to functional node
AKR1B10 has often been read as a disease-associated marker in fatty liver disease, steatohepatitis, fibrosis and liver cancer risk.
That view is becoming too small.
AKR1B10 is a NADPH-dependent aldo-keto reductase. It belongs to carbonyl, aldehyde and retinoid-related stress-handling biology.
In a diseased liver, that matters.
AKR1B10 does not only mark stress.
It may help shape the metabolic state that follows from stress.
That is why recent AKR1B10 work is important. Earlier studies linked AKR1B10 to ACCα stability and the lipogenic machinery that drives de novo lipogenesis and triglyceride synthesis. More recent NASH work placed the AKR1B10/ACCα axis directly within hepatic triglyceride accumulation.
Yang et al. now add another layer.
AKR1B10 appears pharmacologically addressable.
What Yang et al. show
Yang et al. used high-fat diet-fed mice and oleic acid-treated HepG2 cells as experimental NAFLD models.
Berberine improved several metabolic readouts, including hepatic steatosis, triglyceride accumulation, glucose-related parameters and insulin resistance-associated changes.
But the key point is target engagement.
Using a berberine-derived probe and click-chemistry proteomics, the authors identified AKR1B10 among candidate berberine-binding proteins.
They then supported AKR1B10 engagement with additional approaches, including co-localization, molecular docking, SPR, DARTS and CETSA.
Berberine also inhibited AKR1B10 enzymatic activity.
This makes the result stronger than an expression observation.
AKR1B10 is not only increased in disease-associated settings.
It is directly engaged by a small molecule.
The strongest signal is dependence
The most important part of the study is not the target list.
It is the perturbation logic.
In oleic acid-treated HepG2 cells, AKR1B10 knockdown itself increased glucose consumption and reduced triglyceride content.
After AKR1B10 knockdown, berberine produced little or no additional effect on these readouts.
Pharmacological AKR1B10 inhibition supported the same dependency pattern.
AKR1B10 overexpression moved the system the other way: glucose consumption decreased and triglyceride content increased. Berberine counteracted this overexpression phenotype.
The in vivo data point in the same direction. In high-fat diet-fed mice, AAV-mediated AKR1B10 knockdown weakened the additional metabolic effects of berberine.
This is best read as functional dependence.
When AKR1B10 is already reduced or blocked, there is less room for berberine to act.
That is what one expects from a relevant metabolic control point.
Why this matters
A marker can describe disease.
A functional node can help explain how a disease state is maintained.
That is the step AKR1B10 is beginning to take.
Yang et al. do not show that AKR1B10 alone drives NAFLD.
They do not show that berberine treats Detoxification State Fixation.
They do not test the full DSF architecture.
But they do show something important:
AKR1B10 is perturbable.
That matters for a disease-state framework in which stress handling, redox chemistry, lipid remodeling, de novo lipogenesis and lipogenic output may become linked in a self-maintaining hepatic state.
AKR1B10 sits close to that interface.
It connects detoxification-state biology with lipid metabolism.
That is why AKR1B10 should not be read only as a marker of where fatty liver disease has been.
It may be one of the places where the diseased hepatic state can be touched.
A broader pattern is emerging
AKR1B10 may not be standing alone.
A broader progression-level pattern is now emerging.
That pattern deserves its own discussion.
For now, the message is already clear:
AKR1B10 has moved beyond marker status in NAFLD.
Related framework:
Detoxification State Fixation (DSF)
References
Yang, S. et al. Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD. Journal of Ethnopharmacology 332, 118354 (2024). https://doi.org/10.1016/j.jep.2024.118354
Lin, X.-L. et al. Nicotinate-curcumin improves NASH by inhibiting the AKR1B10/ACCα-mediated triglyceride synthesis. Lipids in Health and Disease 23, 201 (2024). https://doi.org/10.1186/s12944-024-02162-5
Ma, J. et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. Journal of Biological Chemistry 283, 3418-3423 (2008). https://doi.org/10.1074/jbc.M707650200
Bitter, A. et al. Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Archives of Toxicology 89, 2089-2103 (2015). https://doi.org/10.1007/s00204-014-1348-x
Related note:
AKR1B10 as a lipogenic control node in NASH